Friday, May 29, 2026

Meeting of the #SAGE on #Immunization, March 2026: conclusions and recommendations {#COVID19 vaccines safety portion} (WHO, May 29 '26)

 


(...)

COVID-19 

    SAGE reviewed the latest epidemiological data on COVID-19 during the Omicron era, including the disease burden and post-COVID conditions, across population groups. 

    Evidence on the status of vaccine use globally and the safety, effectiveness and cost–effectiveness of currently available vaccines was also reviewed. 

    The global burden of severe COVID-19 has declined compared with earlier phases during the pandemic, largely due to widespread population immunity through vaccination and prior infection

    Nevertheless, COVID-19 continues to cause morbidity and mortality, particularly among older adults, individuals with comorbidities and people who are immunocompromised

    In terms of post-COVID-19 conditions, persistent symptoms following acute infection have been documented in both adults and children, although estimates of prevalence vary considerably across studies owing to differences in case definitions and study methods. 

    Vaccination may contribute to reducing the risk of post-COVID-19 conditions, primarily through prevention of severe disease. 

    In terms of the burden of COVID-19 during pregnancy and infancy in the Omicron era, the risk of severe disease and adverse maternal and fetal outcomes was lower than during the pandemic. 

    However, people who are pregnant remain at higher risk of severe disease in the Omicron era compared with those of a similar age who are not pregnant. 

    Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy has been associated with an increased risk of adverse maternal outcomes (e.g. intensive care unit admission) and pregnancy outcomes (e.g. preterm birth). 

    Data on infants infected with SARS-CoV-2, which are mainly from a few high-income settings, indicate that infants aged under 6 months may experience higher hospitalization rates than older children, although the frequency of severe outcomes is low and varies within these settings. 

    The currently available mRNA and protein subunit COVID-19 vaccines have an acceptable safety profile across age groups and risk categories, based on 5 years of accumulated COVID-19 vaccine safety data from clinical trials, post-marketing pharmacovigilance systems, surveillance platforms, post-authorization studies and international regulatory reviews. 

    Serious adverse events remain rare relative to the number of doses administered globally (>13 billion); also, most reported adverse events are mild or moderate and transient, typically resolving within a few days. 

    A limited number of rare, platform-specific adverse events have been identified, including thrombosis with thrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines that are no longer being manufactured, and myocarditis/pericarditis associated with mRNA and protein vaccines

    However, myocarditis and pericarditis associated with the currently available mRNA and protein vaccines remain uncommon, and have a milder course than post-COVID or conventional myocarditis; hence, the overall benefit–risk balance continues to favour vaccination, particularly among populations at increased risk of serious COVID-19 outcomes. 

    Safety following repeated doses, including revaccination with variant-adapted vaccines, remains reassuring, with no new safety signals identified.{24} 

    Real-world evidence consistently shows that the vaccines are effective in reducing COVID-19 associated severe disease and death. 

    Vaccines adapted to Omicron lineages continue to provide meaningful protection against severe outcomes. 

    Routine periodic COVID-19 vaccine doses help to sustain protection, despite the relatively rapid waning of protection against infection and limited protection against symptomatic disease beyond 6 months

    Updated evidence on COVID-19 vaccination during pregnancy from observational studies, pregnancy registries, and surveillance systems across multiple countries has not identified safety concerns

    Currently it shows no increased risk of adverse maternal or pregnancy-related outcomes, including miscarriage, stillbirth, preterm birth or adverse outcomes in infants born to people vaccinated during pregnancy. 

    Vaccination during pregnancy is safe and it provides protection to the pregnant individual, against COVID-19 associated adverse pregnancy outcomes, and to infants aged under 6 months through maternal antibody transfer. 

    Cost–effectiveness analyses of COVID-19 vaccination consistently show that programmes targeting populations at high risk of severe outcomes (e.g. older adults or individuals with underlying health conditions) are generally cost-effective or even cost saving across a range of epidemiological scenarios. 

    Broader vaccination strategies may be cost-effective in certain contexts, depending on disease burden, vaccine costs and programmatic factors. 

    Most studies originate from high-income countries, limiting their generalizability to other settings.

    SAGE recommended that countries should consider routine COVID-19 vaccination for those groups at highest risk of severe COVID-19 disease

    These include oldest adults;{25}  older adults{26} with significant comorbidities or severe obesity; residents in care and long-term care facilities; and individuals aged 6 months or over, who are moderately or severely immunocompromised. 

    For these groups – whether they are unvaccinated or were vaccinated more than 6 months earlier – SAGE recommended at least one dose per year, and preferably two doses administered 6 months apart, owing to the waning of protection against severe COVID-19 disease by 6 months after the last dose. 

    Cost–effectiveness and programmatic feasibility should be considered when determining the number of doses to be administered per year.  

    SAGE also recommended that countries may consider routine COVID-19 vaccination of additional groups based on local context, cost–effectiveness and programmatic feasibility. 

    These additional groups include the following

        Older adults without significant comorbidities or severe obesity; adults (not included in the older adult category), adolescents and children with significant comorbidities or severe obesity; and health workers and other care providers. These groups, whether unvaccinated or previously vaccinated more than 6 months earlier, may be vaccinated with at least one dose per year. 

        People who are pregnant, whether unvaccinated or previously vaccinated more than 6 months earlier. This group may be vaccinated with one COVID-19 vaccine dose during each pregnancy, at any stage, though ideally during the second trimester. The aim is to optimize protection against severe COVID-19 for the pregnant person, prevent adverse pregnancy outcomes and protect the infant during the first months of life. 

        Previously unvaccinated healthy children aged 6–23 months. This age group may be vaccinated if a significant burden is documented; revaccination is not routinely recommended. 

    Some of the research priorities recommended by SAGE were further assessment of the burden, societal impact and vaccine effectiveness against post-COVID-19 condition, using the WHO standardized definition;{27}  studies on cost–effectiveness of COVID-19 vaccination, particularly in low- and middle-income countries, and among groups such as health workers and children; and studies on the social and behavioural drivers of COVID-19 vaccine uptake, to address hesitancy and guide interventions to achieve high confidence and uptake. 

    SAGE recommendations will inform the development of a WHO vaccine position paper on COVID-19 vaccines; the position paper will replace the WHO SAGE interim guidance reflected in the COVID-19 vaccines roadmap.{28} 

(...)

___

{24}   World Health Organization (2026). Global Advisory Committee on Vaccine Safety (GACVS): COVID-19 vaccines – Subcommittee. Geneva: WHO; [cited 2026 Mar 10]. Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/covid-19-vaccines/subcommittee, accessed 30 April 2026).

{25} Age cut-off should be determined by countries – often it is 75 or 80 years. 

{26}  Age cut-off should be determined by countries – often it is 50 or 60 years 

{27} WHO standardized definition for adults: Post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. (https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1, accessed 30 April 2026);  WHO standardized definition for children and adolescents: Post-COVID-19 condition in children and adolescents occurs in individuals with a history of confirmed SARS-CoV-2 infection, with at least one persistent physical symptom lasting for at least 12 weeks after testing positive, that impacts everyday functioning and cannot be explained by another diagnosis. (https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1, accessed 30 April 2026) 

{28} WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1, accessed 30 April 2026)

(...)

Source: 


Link: https://www.who.int/publications/journals/weekly-epidemiological-record

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, May 29 '26)

 


{Excerpt}

(...)

Time Period: May 17, 2026 - May 23, 2026

-- A(H5) Detection7 site(s) (1.6%)

-- No Detection438 site(s) (98.4%)

-- No samples49 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#Italy, Canine #rabies case in Vittorio Veneto: epidemiological #investigations underway. All #dogs and #cats must be vaccinated (LHA, May 29 '26)

 


(No. 97/2026) 

    On Wednesday, May 27, a case of rabies was detected in a crossbreed dog owned by an Italian woman living in the municipality of Vittorio Veneto, in the San Giacomo di Veglia area.

    The case was reported by a veterinary clinic, where the animal had been brought due to the onset of nervous symptoms consistent with the disease. 

    During the medical history reconstruction conducted with the owner and her family, it emerged that the dog had been brought to Italy illegally several months earlier following a tourist trip to Morocco by a relative of the woman.

    Given the animal's extremely serious clinical condition and the potential health risk, the dog was euthanized and immediately transferred to the Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe) – National Reference Center for Rabies, which confirmed the diagnosis and the origin of the virus in Morocco. 

    Rabies is a viral disease spread through direct contact between animals and occasionally from infected animals to humans. 

    The consequences can be very serious, which is why it's important to promptly identify any potential contact with the dog in the previous two weeks. 

    Owners of dogs who may have come into contact with the rabid animal (photo of which is attached to this press release) are encouraged to contact the veterinary services of the Local Health Authority (ULSS).  

    The Public Health and Hygiene Service (SISP) and the Animal Health Service of Local Health Authority 2 have already conducted epidemiological investigations and traced the exposed people and dogs

    The people have been given post-exposure prophylaxis, an effective measure to prevent any risk of disease development, while the dogs will be kept under observation at suitable veterinary facilities within Local Health Authority 2. 

    Health authorities are monitoring the situation and adopting all necessary measures to protect human and animal health. 

    As a precaution, all dogs and cats in the Municipality of Vittorio Veneto must be vaccinated at a veterinary clinic.

    "The case has been monitored with the utmost care from the beginning, and within a couple of days, all possible contacts, both human and animal, were mapped," emphasized Director General Giancarlo Bizzarri. 

    "I therefore believe I can safely say that there is no cause for concern for the Vittorio Veneto population. Anyone with questions or requests for information can reach us via the telephone numbers provided by the ULSS."

    In light of the rabies case recorded in Vittorio Veneto and given that rabies is endemic in numerous non-European countries, ULSS 2 urges everyone to avoid interacting with animals when traveling to "at-risk" countries.

    This afternoon, the Municipality of Vittorio Veneto will publish an ordinance containing practical information for dog and cat owners. 


Contact point for veterinary questions : 336231711 | Contact point for medical questions : 3333360572

Source: 


Link: https://www.aulss2.veneto.it/Caso-di-rabbia-canina-a-Vittorio-Veneto-avviate-le-indagini-epidemiologiche-Tutti-i-cani-e-i-gatti-dovranno-essere-vaccinati

____

#Italy - #Rabies virus (Inf. with) - Immediate notification (WOAH, May 29 '26): Illegal movement of a dog from Morocco

 


{Veneto Region} The case is linked to the illegal movement of a dog originating from Morocco, which transited through Spain before entering Italy in mid-December 2025. The animal was euthanised, and rabies was confirmed by laboratory testing on 27 May 2026.

Source: 


Link: https://wahis.woah.org/#/in-review/7578

____

#Taiwan CDC: In response to escalating #Ebola #outbreak, entry from #DRC and #Uganda will be suspended for 90 days (May 29 '26)

 


    The Centers for Disease Control (CDC) stated today (May 29) that, according to data released by the WHO as of May 27, 2026, the Ebola virus Disease outbreak continues to expand in the Democratic Republic of Congo (DRC) and Uganda, primarily affecting Ituri, North Kivu, and South Kivu provinces within the DRC. 

    The DRC has reported a cumulative total of 906 cases (223 deaths) and 125 confirmed cases (17 deaths). 

    Uganda has reported a cumulative total of 7 confirmed cases to date, including 1 death

    Based on the assessment of the Taiwan Centers for Disease Control (CDC), the Ebola outbreaks in the Democratic Republic of Congo and Uganda are likely to continue to escalate

    In addition to strengthening cross-airport joint prevention and control measures and enhancing port monitoring and interception mechanisms, Taiwan, in order to further reduce the risk of imported cases and referencing practices in the United States and Canada, has jointly discussed with the Ministry of Foreign Affairs and the Bureau of Consular Affairs, the National Immigration Agency of the Ministry of the Interior, and the Civil Aeronautics Administration of the Ministry of Transportation and Communications, and will implement new border epidemic prevention and control measures as follows:

    I. Starting from 00:00 on June 2, 2026, the issuance of visas to residents of the Democratic Republic of Congo and Uganda will be suspended; those already issued visas will have their entry temporarily suspended for 90 days. However, the following four categories of individuals will be excluded:

        ° (I) Students who have already obtained admission permission from Taiwan

        ° (II) Diplomatic and official duties

        ° (III) Spouses of Taiwanese citizens who are not Taiwanese citizens and their minor children

        ° (IV) Emergency or humanitarian assistance: such as attending funerals or visiting seriously ill relatives.

    II. Taiwanese citizens who have traveled to epidemic areas within 21 days prior to entry, holders of valid Taiwanese residence permits, and those permitted to enter Taiwan are still subject to the measures announced by the Centers for Disease Control and Prevention (CDC) on May 27. They must proactively report to the airport quarantine station upon arrival in Taiwan, where quarantine personnel will issue an "Inbound Passenger Self-Health Management Notice." They must conduct self-health management for 21 days after entry, and follow the requirements of the notice to report their health status. If symptoms appear, they should immediately call the epidemic prevention hotline 1922 for assistance from health authorities.

    The CDC explained that the aforementioned control measures will be adjusted in a timely manner based on the latest international epidemic situation and the epidemic prevention risks at Taiwan's borders. The CDC reiterated that the travel epidemic recommendation level for the Democratic Republic of Congo (DRC) and Uganda is Level 3 "Warning," urging the public to avoid all non-essential travel to these countries.

    The Taiwan Centers for Disease Control (CDC) reiterates that, to strengthen border quarantine, in addition to enhancing public awareness through airport multimedia electronic billboards, scrolling displays, and signage, it has been making in-flight announcements on all international flights arriving in Taiwan since May 27th. 

    Passengers who have traveled to the Democratic Republic of Congo or Uganda within the past 21 days are urged to proactively report to the quarantine station upon arrival in Taiwan for TOCC and health assessment. 

    Please cooperate with the following quarantine measures:

        ° 1. Passengers assessed as having suspected Ebola virus infection symptoms (fever, headache, muscle pain, nausea, vomiting, abdominal pain, diarrhea, or bleeding, etc.) will be immediately transported by ambulance to a contracted hospital for examination, and local health authorities will be coordinated in their prevention and control efforts.

        ° 2. Asymptomatic passengers will be issued a "Notice of Self-Health Management for Passengers with Travel History to Ebola-Epidemic Areas." Upon arrival, please cooperate with 21 days of self-health management, keep your phone accessible for contact tracing by health authorities, take your temperature twice daily (morning and evening), and report your health status to the "Public Proactive E-Reporting System." If you experience any of the above symptoms, please call the epidemic prevention hotline 1922 immediately for assistance from the Health Bureau to seek medical attention. Those who do not cooperate with the above measures will be penalized in accordance with the Infectious Disease Prevention and Control Act.

Source: 


Link: https://www.cdc.gov.tw/Bulletin/Detail/64WhLC3Lcr6B4QUo04UA6A?typeid=9

____

Increased burden of #influenza #H1N1pdm09 in older adults following the #COVID19 #pandemic

 


Abstract

Of the two influenza A virus (IAV) subtypes circulating endemically in humans, A/H3N2 and A/H1N1pdm09, A/H3N2 has historically been the dominant driver of disease burden in older adults. Based on an analysis of publicly available global surveillance data from 2015 to 2025 (>300,000 subtyped, age-stratified infections), we report a substantially increased contribution of A/H1N1pdm09 to influenza morbidity in older adults since approximately 2022. Birth cohort-stratified analyses suggest elevated A/H1N1pdm09 burden among individuals born before 1955-1959, consistent with erosion of pre-existing immunity originally generated by exposure to historical A/H1N1 strains. Pooled estimates across datasets and analytical approaches indicate the increase in A/H1N1pdm09 burden rises with earlier birth year, ranging from 1.22-fold (95% CI 1.08-1.37) for the 1955-1959 birth cohort to 3.10-fold (95% CI 2.58-3.72) for the 1930-1934 cohort. These findings point to a substantial rise in the overall influenza burden among the most vulnerable age groups, with implications for vaccine policy, clinical management, and public health planning.


Competing Interest Statement

C.A.R. has received consulting fees from CSL Seqirus, Moderna, Pfizer, GSK, and Sanofi for advisory services unrelated to this work.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.05.20.26353664v1

____

Thursday, May 28, 2026

Experts convened by #WHO advise on candidate #treatments and #vaccines for #Ebola disease caused by #Bundibugyo virus (WHO, May 28 '26)

 


    In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups

    These groups assessed potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD). 

    The WHO advisory groups recommended that all the products identified and considered be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.

    WHO convened a series of meetings with the WHO R&D Blueprint technical advisory groups on candidate vaccines and therapeutics for BVD.

    In parallel, WHO also convened the Strategic Advisory Group of Experts on Immunization (SAGE) and its Ebola vaccine working group to advise on the potential role of licensed Ebola vaccines during BVD outbreaks.


Key recommendations

    There are currently no licensed therapeutics or vaccines specifically approved for the prevention and treatment of BVD. 

    Nevertheless, WHO advisory groups considered several candidate products that are promising enough to warrant prioritization for evaluation in clinical trials. 

    WHO is now working closely with the governments of the Democratic Republic of the Congo and Uganda to facilitate the implementation of research evaluation of these products.

    For treatment of cases:

        ° For treatment, the independent experts recommended prioritizing three candidate therapeutics for evaluation in research (i.e. clinical trials) among confirmed BVD cases: the monoclonal antibodies MBP134 and Maftivimab®, as well as the antiviral remdesivir.

        ° Combination therapy using a monoclonal antibody and remdesivir is also recommended for evaluation.

    For prevention of cases:

        ° For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was determined to be a priority candidate, although experts noted that this approach depends on effective contact tracing, which remains operationally challenging in some of the affected areas of the Democratic Republic of the Congo. Research on post-exposure prophylaxis involves giving tablets of obeldesivir to contacts of cases to evaluate whether this prevents them from developing Ebola disease.

        ° The most promising candidate vaccine was determined by the experts to be the single-dose rVSV Bundibugyo vaccine (being developed by the International AIDS Vaccine Initiative or IAVI). The development of this single-dose vaccine candidate will likely require 7–9 months before it is ready to be assessed through a clinical trial for its ability to prevent BDV.

        ° Another candidate vaccine, ChAdOx1 Bundibugyo (being developed by Oxford University/Serum Institute of India) could potentially become available within 2–3 months for efficacy assessment through a clinical trial.  However, additional animal data are still required to support and confirm further prioritization. Experts noted that a single-dose vaccine approach of this candidate could be suitable for contacts of Ebola cases, whereas a two-dose strategy might be considered for high-risk but unexposed populations such as health-care workers and frontline responders.

        ° The convened experts also reviewed the potential role of Ervebo, the only licensed Ebola vaccine. It is approved for use during outbreaks caused by the most common Ebola virus in Africa, from the Orthoebolavirus family. Ervebo is not licensed for prevention of BVD and evidence on cross-protection to other Ebola virus species remains limited and inconclusive. WHO recommends that Ervebo should not be used outside carefully designed research settings, to allow for its performance against BDV to be assessed.


Ensuring ethical and safe clinical trials

    WHO, the governments of the Democratic Republic of the Congo and Uganda, the Africa Centres for Disease Control and Prevention (Africa CDC), the ANRS Emerging infectious diseases (French National Agency for Research on AIDS and Viral Hepatitis), and other scientific partners are working together to develop and implement appropriate protocols to assess the safety and efficacy of the prioritized therapeutics through clinical field trials.

    WHO calls for accelerated access to essential supplies, stronger community protection, engagement and trust, and coordinated investment in the research, development and evaluation of BVD countermeasures.

    All research must adhere to the highest ethical standards, under the leadership of the national health authorities and in close consultation with affected communities.

    In the meantime, our priority is to stop transmission with tools that we have used for decades of Ebola responses, which include disease surveillance, rapid testing and diagnosis, contact tracing, isolation and care for patients, infection prevention and control, community engagement, and safe and dignified burials.


Background

    The WHO R&D Blueprint is a global initiative that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of proven effective tests, vaccines, and medicines that can be used to save lives and avert large-scale crises.

    SAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions.


About WHO 

    Dedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life.

    We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable. 

    “Together for health. Stand with science”, the theme of World Health Day 2026 marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide.

Source: 


Link: https://www.who.int/news/item/28-05-2026-experts-convened-by-who-advise-on-candidate-treatments-and-vaccines-for-ebola-disease-caused-by-bundibugyo-virus

____

#Bundibugyo virus disease, multi-country - Situation #Update (#UK HSA, May 28 '26): 1,198 cases and 263 deaths in #DRC



{Excerpt}

    The following relates to an ongoing outbreak, with data current to 27 May 2026

    ° Disease or pathogen: Bundibugyo virus disease (BVD)

    ° Location: Multi-country

    ° Status: Update

    ° Reporting date: 15 to 27 May 2026


Summary

    -- On 15 May 2026, an outbreak of Ebola disease caused by Bundibugyo virus was declared in the Democratic Republic of the Congo (DRC) and Uganda

    -- On 16 May 2026, the WHO Director-General determined that the outbreak constitutes a public health emergency of international concern.

    -- As of 26 May 2026, 1,198 Bundibugyo virus cases (including 1,077 suspected and 121 confirmed) and 263 deaths (246 suspected and 17 confirmed) have been reported in the DRC

    -- Confirmed cases have been reported in Ituri (110 cases), North Kivu (10 cases), and South Kivu (one case) provinces.

    -- In Uganda, as of 27 May 2026, 7 confirmed cases (including one death) have been reported. 

    -- This is an increase of 5 confirmed cases since the last report. 

    -- The US Centers for Disease Control and Prevention reported that the 5 new cases have clear links to the first 2 confirmed cases.

    -- On 22 May 2026, Charite University Hospital in Berlin reported that the citizen of the United States who was medically evacuated from the Democratic Republic of the Congo with Ebola disease, has tested positive for Bundibugyo virus upon confirmatory testing. The case is under observation and receiving treatment in the high-security area of the hospital’s specialised isolation unit. The case’s wife and children, who are classified as high-risk contacts, are currently asymptomatic and quarantined in a separate part of the unit. Initial Ebola PCR tests for the family members were negative.

    -- To control the spread of the outbreak, WHO has supported with the deployment of rapid response teams, the delivery of medical supplies and the strengthening of surveillance. Other response activities include infection prevention and control assessments, the set-up of safe treatment centres, and community engagement.

    -- On 21 May 2026, the United Kingdom announced that it has allocated up to £20 million in new aid funding to the response to the outbreak.

    -- This represents the 17th recorded outbreak of Ebola disease in the DRC since the virus was first identified in 1976, with the last reported outbreak ending in December 2025 in Kasai Province. Bundibugyo virus was first identified in 2007 in Bundibugyo district, western Uganda. A second outbreak caused by Bundibugyo virus was reported in DRC in 2012.

    -- As of 27 May 2026, no imported cases associated with this outbreak have been reported in the UK. Previously in 2015, an imported case of Ebola virus disease was reported in the UK associated with the 2014 to 2016 West Africa outbreak.

    -- The WHO assesses the risk of this event as low at a global level, high at the regional level and very high at a national level. 

    -- The risk of the current Ebola outbreak to the UK population is assessed as low.


Further information

    ° Ebola: overview, history, origins and transmission

    ° Ebola virus disease: clinical management and guidance

    ° Ebola and Marburg haemorrhagic fevers: outbreaks and case locations

    ° UKHSA blog:  What is Ebola and how does it spread?

    ° Algorithm for the management of samples suspected of Ebola Virus Disease (in Spanish)

    ° NaTHNaC country information page: Democratic Republic of the Congo and Uganda

(...)

Source: 


Link: https://www.gov.uk/government/publications/outbreaks-under-monitoring-in-2026/outbreaks-under-monitoring-week-21-week-ending-24-may-2026

____

#Hantavirus #infections: an emerging zoonotic #threat in the context of #ecological change

 


{Extract}

Dear Editor,

Hantaviruses, belonging to the family Hantaviridae, are increasingly recognized as significant zoonotic pathogens responsible for severe human diseases, including hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). Although traditionally considered geographically confined, recent epidemiological data indicate a gradual expansion in the incidence and geographic distribution of hantavirus infections, raising concerns regarding their re-emergence as a global public health threat [1,2]. 

(...)

Source: 


Link: https://www.sciencedirect.com/science/article/pii/S2052297526000673?via%3Dihub

____

#Hantavirus #outbreak linked to cruise ship #travel, Multi-locations (WHO D.O.N., May 28 '26)

 


Situation at a glance

    -- This is the fourth Disease Outbreak News report on the Andes hantavirus outbreak linked to cruise ship travel, following the notification to the World Health Organization (WHO) on 2 May 2026 of severe respiratory illness cases aboard M/V Hondius, a cruise ship

    -- Since the last DON was published on 13 May, three additional confirmed cases were reported, from Canada, the Netherlands, and Spain

    -- The previously reported inconclusive case from the United States of America was subsequently determined to be negative following further laboratory testing and has been removed from the total case count. 

    -- All cases to date have been passengers or crew members on the ship. 

    -- As of 27 May, a total of 13 cases, including three deaths, have been reported (case fatality ratio 23%). 

    -- Eleven cases have been laboratory-confirmed for Andes virus (ANDV) infection, and two are probable cases

    -- Given the long incubation period of up to six weeks, it is not unexpected that cases continue to be reported until the end of the six weeks since last exposure. 

    -- Through the International Health Regulations (2005) (IHR) channels, National IHR Focal Points (NFPs) have all been informed and are supporting international contact tracing and monitoring efforts. 

    -- WHO has assessed the risk posed by this event to the global population as low and will continue to monitor the epidemiological situation and update the risk assessment as needed.


Description of the situation

    -- On 2 May 2026, WHO received notification from the IHR NFP of the United Kingdom of Great Britain and Northern Ireland (hereafter referred to as the United Kingdom) regarding a cluster of severe acute respiratory illness, including two deaths and one critically ill passenger, aboard the Netherlands-flagged cruise ship M/V Hondius.

    -- As of 27 May, a total of 13 cases (eleven confirmed and two probable cases), including three deaths (two confirmed and one probable), have been reported. 

    -- Since the last Disease Outbreak News was published on 13 May, three additional confirmed cases have been reported among passengers or crew members, one each from Canada, the Netherlands, and Spain

    -- The case in Canada developed symptoms during contact follow-up, whereas the cases in the Netherlands and Spain were identified through routine weekly testing of high-risk contacts during follow-up. 

    -- The previously reported inconclusive case from the United States of America was subsequently determined to be negative following further laboratory testing and has been removed from the total count on 15 May. 

    -- All confirmed cases are among people who travelled onboard the M/V Hondius.

__

Figure 1. Epidemiological curve of Andes hantavirus cases (n = 13) reported to WHO as of 27 May 2026, 17:00


{Ckick on Image to Enlarge}

___

    -- Based on currently available information, the working hypothesis is that the first case acquired the infection prior to boarding the cruise, through exposure on land

    -- Investigations are ongoing to elucidate the potential circumstances of exposure and the source of the outbreak, in collaboration with authorities in Argentina and Chile, however, the time between the individual’s visit to Chile and the onset of symptoms exceeds the maximum incubation period. 

    -- Therefore, based on the information currently available, exposure in Chile can be ruled out

    -- Current evidence suggests subsequent human-to-human transmission onboard the ship. 

    -- This is also supported by a preliminary analysis of the sequences, which show a near-identical sequence from different cases.[1]

    -- This outbreak is being managed through a coordinated international response

    -- This includes comprehensive epidemiological investigations, case isolation and clinical management, medical evacuations, laboratory testing, and international contact tracing, as well as quarantine and monitoring measures. 

    -- Recommendations are subject to change as new epidemiological and laboratory evidence becomes available, including findings from genetic sequencing.

    -- Follow-up and contact tracing for all contacts of hantavirus cases linked to the cruise ship is ongoing. This includes passengers who disembarked in Saint Helena, United Kingdom, on 24 April; Ascension, United Kingdom, on 27 April; Praia, Cabo Verde, on 6 May; and Tenerife, Spain, on 10 and 11 May, the remaining 25 crew members and the two healthcare workers from the Netherlands who disembarked in the Netherlands on 18 May and 23 May. Passengers who travelled on flights who may have had exposure to subsequently confirmed cases have been identified and contacted.

    -- High-risk contacts are being quarantined and monitored by local health authorities either in their respective countries or in the ship’s flag country, the Netherlands, or third countries (Table 1). 

    -- As of 22 May 2026, more than 600 contacts, including 53% high-risk and 47% low-risk contacts, have been identified across 32 countries, territories and areas, and are either under close monitoring or self-monitoring in line with the updated guidance on management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship   published on 17 May.

___

Table 1. Contacts being traced for the Andes hantavirus outbreak on a cruise ship reported to WHO as of 25 May 2026, 17:00.


{Click on Image to Enlarge}

___

Epidemiology

    -- Hantavirus disease is a zoonotic viral disease caused by hantaviruses of the genus Orthohantavirus, family Hantaviridae, order Bunyavirales. More than 20 viral species have been identified within this genus.  

    -- Human hantavirus infection is primarily acquired through contact with the urine, faeces, or saliva of certain species of (specific) infected rodents, or by touching contaminated surfaces. 

    -- Exposure typically occurs during activities such as cleaning buildings with rodent infestations, though it may also occur during routine activities in heavily infested areas. 

    -- Human cases are most commonly reported in rural settings, such as forests, fields, and farms, where rodents are present, and opportunities for exposure are greater.

    -- Human-to-human transmission has currently only been reported for hantavirus pulmonary syndrome (HPS) associated with Andes virus infection

    -- Andes virus (ANDV) is endemic in South America, with confirmed circulation and human cases reported primarily in Argentina and Chile, and additional cases and related strains identified in Uruguay, southern Brazil, and Paraguay.


Andes virus transmission between humans

    -- Based on the available information and the existing observations of the current outbreak, limited human-to-human transmission of ANDV is known to occur

    -- However, no large-scale human-to-human outbreaks have been observed historically,[2] suggesting a low probability of transmission per contact. 

    -- ANDV circulates in specific species of rodents in the Americas, and there have been many sporadic cases reported in Argentina and Chile that have not led to onward transmission.[3] 

    -- Clusters of human cases have been reported in multiple past outbreaks and have been typically associated with close and prolonged interactions, often in shared indoor environments such as households.  

    -- The largest reported outbreak of ANDV was reported in Argentina in 2018-2019,[2] where high viral titres in combination with attendance at large social gatherings or extensive contacts among people were associated with higher transmission.  

    -- While the available evidence suggests that there are multiple modes of transmission that occur with ANDV, the probability of onward transmission between humans remains low.

    -- In this recent outbreak of ANDV infection reported on a cruise ship, human-to-human transmission has also occurred

    -- Considering the ongoing epidemiological studies and environmental sampling after the disembarkation of all passengers from MV Hondius, the exact mode(s) through which human-to-human transmission occurred and their relative contributions are yet to be fully understood

    -- Therefore, at present, WHO is operating under the assumption that ANDV transmission:

        ° may include contact with an infected individual or contaminated surfaces,

        ° and/or through-the-air transmission (via direct deposition of infectious respiratory particles onto exposed facial mucosal surfaces--mouth, nose or eyes)

        ° and/or airborne transmission (via inhalation of infectious respiratory particles).

    -- The virus does not exhibit transmission dynamics consistent with highly transmissible airborne pathogens (such as measles).

    -- This information is up to date as of 27 May 2026. It will be updated as new evidence becomes available and the understanding of transmission evolves.

    -- Using data from the previously documented human-to-human outbreaks in Argentina [2] and the 13 cases so far recorded from the cruise ship outbreak, WHO estimates that the mean incubation period is 22 days, corresponding to a probability of safe release from quarantine of 96% at 42 days, reducing to 91% at 35 days. This reaffirms WHO’s recommendation of 42 days of quarantine for high-risk contacts and self-monitoring for low-risk contacts.

    -- Using case incidence data from the ANDV outbreak associated with the cruise ship, the effective reproduction number (Rt) for this outbreak as of 22 May is estimated to be 0.7, where anything less than 1.0 indicates that the spread of disease is declining. 


Public health response

    -- Authorities from States Parties managing cases and/or contacts, WHO, and partners have initiated coordinated response measures, including:

        ° Ongoing engagement between WHO and the IHR NFPs of countries managing cases and/or contacts to ensure timely information sharing and coordination of response actions.

        ° International contact tracing and follow up of contacts is ongoing.

        ° WHO is requesting regular information sharing and periodic updates from States Parties through IHR channels regarding contact monitoring and the health status of high-risk contacts.

        ° Epidemiological investigations continue to better define epidemiological links between cases and exposure factors on the ship, as well as to try to understand the potential source of exposure.

    -- WHO has developed and published specific technical guidance documents to support response to the event, including:

        ° Technical guidance on the management of hantavirus onboard ships was shared with States Parties through IHR channels

        ° Technical note for the disembarkation and onward management of passengers and crew in the context of an Andes-virus-associated cluster;

        ° Management of contacts of Andes Virus (ANDV) cases from the MV Hondius cruise ship

    -- IHR NFPs of affected countries have been in contact about passenger and crew    information through established IHR channels for those who were on the ship, as well as on planes where a known case was on board. Nearly 1000 communications have occurred through these established channels.

    -- Risk communication coordination and support are being provided to ensure sharing of regular, timely and evidence-based information. WHO has activated three-level coordination and is supporting national authorities in implementing risk-based, evidence-informed public health measures in accordance with the provisions of the IHR and related WHO technical guidance documents.

    -- WHO regularly convenes expert calls across laboratory, clinical management, epidemiology, infection prevention and control (IPC), and border health and points of entry domains to facilitate timely experience sharing and coordinated expert support.

    -- WHO has supported the streamlining and development of research protocols on the natural clinical history in collaboration with national partner institutions and planned a hantavirus scientific consultation on medical countermeasures.


WHO risk assessment

    -- WHO continues to assess the risk for passengers and crew who were onboard the cruise ship as moderate, as individuals exposed prior to the implementation of control measures may still develop illness during the incubation period and should therefore be closely monitored.

    -- The risk at the global level is assessed as low for the following reasons:

        ° Andes virus has demonstrated limited human-to-human transmission in previous outbreaks, typically occurring among close contacts and within household settings, generally requiring prolonged close exposure. 

        ° Transmission can be contained through early detection, isolation of cases, clinical management, and contact management. However, the ship environment presented an increased risk due to close living quarters, shared indoor spaces, prolonged exposure, and frequent interpersonal interactions, all of which likely facilitated transmission.

        ° Human Pulmonary Syndrome caused by hantaviruses in the Americas, including Andes virus, can have a high case fatality ratio, reaching 40-50%, particularly among elderly individuals and those with co-morbidities. The average age of passengers on board the ship was 65 years old.

        ° Investigations on the travel history and potential exposures of the first case in the Southern Cone subregion of the Americas are ongoing and suggest possible exposure to rodents during recreational activities. Viral sequencing analyses are also ongoing and are comparing the ANDV strain associated with this outbreak with strains circulating in Argentina and Chile, where the disease is enzootic. The preliminary sequencing analysis for the cases indicates a high degree of genetic similarity amongst sequenced cases —showing no more than one single nucleotide polymorphisms difference per individual – which strongly indicates that the outbreak likely arose from a single zoonotic spillover event, or from a very small number of closely related spillover events.[1]

    -- Additional cases may occur among individuals exposed before implementation of containment measures. However, the current response, including quarantine for those who have left the ship and rapid isolation of any new suspect cases and the monitoring of contacts, is expected to limit the risk of further spread.

    -- As there is no specific antiviral treatment for HPS, suspected cases require prompt transfer to an adequately equipped emergency department or intensive care unit, where available, for close monitoring and supportive management to improve chances of recovery. Consequently, for remote areas, rapid transfer to a well-resourced healthcare facility is required, which may be challenging under the current conditions.

    -- For the general public, including people not exposed on board the ship or through close contact with a confirmed case, the overall probability of infection remains low

    -- Current evidence indicates that human-to-human transmission occurs through close and prolonged contact, and can be effectively limited through early detection, isolation of cases, and contact tracing. 


WHO advice

    -- WHO advises States Parties involved in this event to continue coordinated public health management efforts related to the management of cases and contacts associated with the affected ship and flights, as well as in countries where cases and/or contacts have been identified. 

    -- WHO has advised and continues to advise a precautionary approach for management of the outbreak related to the ship, with focus on total containment to minimize the onward risk of transmission to other persons. 

    -- This strategic decision is guided by:

        ° To date, most of the evidence of human-to-human transmission shows it has required prolonged close exposure, although it is possible that some highly infectious individuals could infect others through a lower degree of exposure.

        ° Mode(s) of transmission and which mode is dominant if multiple routes of transmission exist are still uncertain.

        ° Infection is a result of not only exposure, but the setting and duration where exposure has taken place, how infectious the infected person is, and whether personal protective equipment is used.

    -- Although the probability of infection is uncertain, if infection occurs, it can be severe. Currently, there is no specific treatment available and severe disease requires advanced critical care.

    -- There is a relatively low burden of additional infection prevention and control measures.

    -- At this time, WHO does not recommend any changes to routine activities for the general public. People who were on board the affected ship, or who have had close contact with a confirmed case, should follow national health advice. Guidance may be updated as further evidence becomes available.

    -- Recommendations remain dynamic and will be updated as additional epidemiological and laboratory evidence, including genetic sequencing data, becomes available.


Coordination

    -- WHO advises States Parties involved in this event to continue public health coordination related to the management of cases and contacts in countries where they are present or expected to return, as well as of affected conveyances, as applicable and in close coordination with travel and transport authorities, conveyance operators, and other relevant stakeholders at points of entry.

    -- Coordination should ensure the implementation of risk-based, evidence-informed public health measures.


Surveillance

    -- Ongoing epidemiological investigations include detection, investigation, and reporting of suspected cases, as well as contact tracing and monitoring.

    -- As a precautionary measure, high-risk contacts should undergo active monitoring and home or facility quarantine for 42 days following their last exposure.

    -- Current evidence does not support routine laboratory testing or quarantine of low-risk contacts; instead, they should undertake passive self-monitoring and seek medical evaluation if symptoms develop.

    -- Contact tracing and listing should utilize all available information sources, including interviews and relevant conveyance-related documentation (passenger manifests, passenger locator forms, and other relevant activity logs), to ensure completeness.

    -- Early recognition and prompt isolation of suspected cases remain critical to reduce further transmission.


Laboratory

    -- Laboratory testing of suspected cases should be conducted as part of the outbreak response.

    -- Laboratory investigations may include molecular detection, serology, and sequencing to support case confirmation and better understand the outbreak.

    -- Recommendations on laboratory approaches will continue to evolve as new evidence becomes available.


Case management

    -- Early identification, prompt isolation, and clinical evaluation of suspected cases are essential.

    -- When HPS is suspected, patients should be promptly referred for close monitoring and supportive care, including admission to emergency or intensive care settings when needed.

    -- Clinical management is primarily supportive and may include antipyretics, careful fluid management, hemodynamic monitoring, respiratory support, and escalation to advanced interventions for severe cases.

    -- Mechanical ventilation, vasopressors, extracorporeal membrane oxygenation[4] (ECMO), or dialysis may be required for severe disease.

    -- Antibiotics are not routinely indicated for confirmed hantavirus infection, but may be used empirically if bacterial infection cannot be ruled out or is suspected.

    -- Currently, there is no approved specific antiviral treatment for HPS.


Infection Prevention and Control

    -- Suspected or confirmed cases should be isolated in a single, well-ventilated room.

    -- Standard precautions* should be applied at all times for all patients, including hand hygiene, environmental cleaning, and appropriate waste management, outlined in the interim guidance published on 8 May

    -- Transmission-based precautions should be implemented in addition to standard precautions. Health and care workers should use appropriate personal protective equipment, including respirators, eye protection, gowns, and gloves.

    -- Suspected or confirmed cases should be isolated in a single, well-ventilated room.

    -- Transmission-based precautions should be implemented in addition to standard precautions.

    -- Hand hygiene should be performed before and after the use of PPE.

    -- Waste from suspected or confirmed cases should be managed as infectious waste.

    -- Airborne precautions should be applied during aerosol-generating procedures.

    -- The duration of standard and transmission-based precautions should be determined on a case-by-case basis.


Risk Communication and Community Engagement (RCCE)

    -- Communication strategies should prioritize transparent, timely, and culturally appropriate information to affected individuals and the general public.

    -- Risk Communication and Community Engagement (RCCE) efforts should provide clear, consistent, and actionable information, including explanations of the public health measures being implemented.

    -- Messaging should address public concerns regarding transmissibility, severity, and international travel, and clarify recommended actions for different population groups.

    -- Public health awareness should focus on early detection, timely healthcare seeking, and reducing exposure risks, including occupational and environmental exposures.

    -- RCCE activities should be integrated throughout all phases of the response and align with broader public health measures.

    -- Environmental management strategies, including rodent control, should be included as part of prevention efforts.

    -- Based on the current information available on this event, WHO advises against the application of any travel or trade restrictions beyond the restriction of movement of identified high-risk contacts.

___

{*} Standard precautions refer to a set of practices that are applied to the care of patients, regardless of the state of infection (suspicion or confirmation), in any place where health services are provided. These practices aim to protect both healthcare professionals and patients and include hand hygiene, use of personal protective equipment, respiratory hygiene and cough etiquette, safe handling of sharps materials, safe injection practices, use of sterile instruments and equipment and cleaning of hospital environments and the environment. Adapted from “Standard precautions for the prevention and control of infections: aide-memoire”- WHO, 2022.  Available at https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2022.1  


Further information

    -- World Health Organization. Management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship. https://www.who.int/publications/m/item/management-of-contacts-of-andes-virus-(andv)-cases-fromthe-mv-hondius-cruise-ship

    -- World Health Organization. WHO Technical note for the disembarkation and onward management of passengers and crew in the context of an Andes virus-associated cluster MV Hondius cruise ship. https://www.who.int/publications/m/item/who-technical-note-for-the-disembarkation-and-onward-management-of-passengers-and-crew-in-the-context-of-an-andes-virus-associated-cluster-mv-hondius-cruise-ship

    -- World Health Organization. Hantavirus fact sheet. https://www.who.int/news-room/fact-sheets/detail/hantavirus 

    -- World Health Organization.WHO’s response to hantavirus cases linked to a cruise ship. https://www.who.int/news/item/07-05-2026-who-s-response-to-hantavirus-cases-linked-to-a-cruise-ship

    -- World Health Organization. Handbook for management of public health events on board ships. https://www.who.int/publications/i/item/9789241549462

    -- World Health Organization. Guide to Ship Sanitation, 3rd edition https://www.who.int/publications/i/item/9789241546690

    -- World Health Organization. Handbook for management of public health events in air transport, https://www.who.int/publications/i/item/9789241510165

    -- World Health Organization. Guide to hygiene and sanitation in aviation, 3rd edition, https://www.who.int/publications/i/item/9789241547772

    -- Preliminary analysis of Orthohantavirus andesense virus sequences from a cruise-ship related cluster, May 2026. https://virological.org/t/preliminary-analysis-of-orthohantavirus-andesense-virus-sequences-from-a-cruise-ship-related-cluster-may-2026/1029

    -- World Health Organization. Standard precautions for the prevention and control of infections: aide-memoire. https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2022.1

    -- World Health Organization. Transmission-based precautions for the prevention and control of infections: aide-memoire. https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2022.2

    -- World Health Organization. Hantavirus outbreak toolbox. https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/hantavirus-outbreak-toolbox

    -- World Health Organization (8 May 2026). Disease Outbreak News. Hantavirus cluster linked to cruise ship travel, Multi-country. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON600

    -- World Health Organization (4 May 2026). Disease Outbreak News. Hantavirus cluster linked to cruise ship travel- Multi-country. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON599

    -- World Health Organization. A decision framework for effective, equitable and context-specific public health and social measures during public health emergencies: decision navigator: https://iris.who.int/server/api/core/bitstreams/ceaf4aa7-00c8-4681-9c35-965e231a3706/content

    -- Pan American Health Organization / World Health Organization. Infection prevention and control of hantavirus infection, including Andes virus disease. Interim regional guidance for suspected or confirmed cases. https://iris.paho.org/items/bc5a7b5a-5a0a-4407-829e-663c762ad615

    -- Pan American Health Organization / World Health Organization. Clinical management of hantavirus infection, including Andes virus disease: Interim regional guidance for suspected or confirmed cases. https://iris.paho.org/items/0fa0dcb1-4395-467d-a431-5408b4eff337    

    -- Pan American Health Organization / World Health Organization. PAHO supports the international response to hantavirus pulmonary syndrome cases linked to a cruise ship in the Atlantic. https://www.paho.org/en/news/7-5-2026-paho-supports-international-response-hantavirus-pulmonary-syndrome-cases-linked

    -- Epidemiological Alert Hantavirus Pulmonary Syndrome (HPS). https://www.paho.org/en/documents/epidemiological-alert-hantavirus-pulmonary-syndrome-americas-region-19-december-2025  

    -- Hantavirus in the Americas: Guidelines for diagnosis, treatment, prevention and control. Available at: https://iris.paho.org/handle/10665.2/40176

    -- Hantavirus Prevention, CDC: https://www.cdc.gov/hantavirus/prevention/?CDC_AAref_Val=https://www.cdc.gov/hantavirus/hps/prevention.html

    -- MartĂ­nez Valeria, Paola N, et al. (2020). “Super-Spreaders” and Person-to-Person Transmission of Andes Virus in Argentina. New England Journal of Medicine. 383. 2230-2241. 10.1056/NEJMoa2009040.

    -- US CDC. How to Clean Up After Rodents: https://www.cdc.gov/healthy-pets/rodent-control/clean-up.html

    -- Hantavirus, Washington State Department of Heath, https://doh.wa.gov/sites/default/files/2025-08/420-056-Guideline-Hantavirus.pdf

    -- Hantavirus Infection, MDS Manual, professional version: https://www.msdmanuals.com/professional/infectious-diseases/arboviruses-arenaviridae-and-filoviridae/hantavirus-infection

    -- Hantavirus pulmonary syndrome, https://www.mayoclinic.org/diseases-conditions/hantavirus-pulmonary-syndrome/symptoms-causes/syc-20351838


___

[1] Preliminary analysis of Orthohantavirus andesense virus sequences from a cruise-ship related cluster, May 2026. https://virological.org/t/preliminary-analysis-of-orthohantavirus-andesense-virus-sequences-from-a-cruise-ship-related-cluster-may-2026/1029

[2] “Super-Spreaders” and Person-to-Person Transmission of Andes Virus in Argentina | New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2009040

[3] Padula PJ, Edelstein A, Miguel SD, LĂ³pez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology. 1998 Feb 15;241(2):323-30. doi: 10.1006/viro.1997.8976. PMID: 9499807.  https://pubmed.ncbi.nlm.nih.gov/9499807/

[4] Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. The Journal of Thoracic and Cardiovascular Surgery. 2008;135(3):579-584. doi:10.1016/j.jtcvs.2007.11.020. 


Citable reference: World Health Organization (28 May 2026). Disease Outbreak News. Hantavirus outbreak linked to cruise ship travel, Multi-locations. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON604

Source: 


Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON604

____

My New Space

Most Popular Posts